This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Considering how much flak she got after wearing sky-high Manolo Blahniks to visit hurricane victims in Texas last year, one of her first major style missteps as a first lady, it is ludicrous to imagine anything Melania Trump wore after that incident was less than studied and well thought-out.
LOS ANGELES—At 65 years old, Pierce Brosnan still cuts a dashing figure. The actor, wearing an embossed navy Armani jacket, blue Brioni shirt, black pants and Jimmy Choo shoes, looked like he could still resume playing James Bond, on a recent afternoon at the Grand Hotel in Stockholm, Sweden.
Among the retailers and brands that could be most impacted from the proposed 10% tariffs on $200 billion in Chinese goods are Best Buy Co. Inc., Michael Kors Holdings Ltd., and Coach parent Tapestry Inc., say analysts.
WFC CHOO WFCNP WFC.WS BURL WFC.PRL WFC.PRJ JYMHF FOSL WFC.PRT DLTR WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN KORS DG KATE WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Shares of Michael Kors Holdings Limited (KORS - Free Report) have underperformed the industry in the past three months. The stock has gained 1.7%, underperforming the industry’s rise of 12.9%. Analysts pointed that year-over-year decline in the bottom line during the fourth quarter of fiscal 2018 hurt investor sentiment. Further, the company continues to witness dismal wholesale segment performance.
CHOO UA UAA KORS LULU ADI JYMHF GIII
TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- First Capital Realty Inc. (“First Capital” or the “Company”) (TSX:FCR), one of Canada’s largest owners, developers and managers of grocery anchored, retail-focused urban properties, announced today that it has acquired or entered into agreements to acquire several high quality properties in core urban markets in Canada (collectively the “Acquisition Properties”) and that it has commenced the development of two currently owned assets (collectively the “Development Assets”) which represent an aggregate capital requirement of approximately $300 million at the Company’s share.
CHOO FCR.DB.H FCR.DB.I FCRGF FCR.DB.J FCAP JYMHF FCR FCR.DB.E
The much awaited IIFA 2018 frenzy that spanned over the weekend witnessed a starry turnout from the Bollywood fraternity. Touted to be the grandest celebration of Indian Cinema, this year IIFA put on a show in the cosmopolitan city of Bangkok, Thailand. Friday fervor witnessed the customary press conference where the stars interacted with the media, regaling with their shenanigans. The evening saw these stars join in the musical revelries in a never-before seen medley at IIFA Rocks 2018.
I issued a strong buy rating to Michael Kors (KORS) and published a research report for Consumer Alpha subscribers back in July, when there was only one buy rating among 21 Wall Street analysts covering the stock. We held the stock in Consumer Alpha’s portfolio until recently, when we closed our position with a 94% profit. The stock was fairly valued without particularly strong catalysts to drive substantial upside, and that’s why I decided to put my money into ideas that offered better opportunities.
CHOO DB JYMHF
The New York-based Michael Kors Holdings Limited (KORS) reported its results for the fourth quarter of 2018 on Wednesday. The results relate to the three-month period ending March 31.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET